Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    KoçSistem Leads Türkiye’s IT System Integrator for the Eighth Consecutive Year as KoçDigital Wins Top AI Award

    August 9, 2026

    Magnitude 4.9 earthquake hits southwestern China in Sichuan

    August 8, 2026

    Obesity linked to 8.2% of Belgium deaths in new health report

    August 8, 2026
    Facebook X (Twitter) Instagram
    • Home
    • Contact Us
    Sudan GuardianSudan Guardian
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Sudan GuardianSudan Guardian
    Home » MAYPHARM CO., LTD. Launches SKINCOLLA: The World’s First Recombinant Human Collagen Filler for Superior Skin Rejuvenation
    PR Newswire

    MAYPHARM CO., LTD. Launches SKINCOLLA: The World’s First Recombinant Human Collagen Filler for Superior Skin Rejuvenation

    February 14, 2025
    Facebook Twitter Pinterest LinkedIn Telegram Tumblr Email

    Groundbreaking Technology Combines Recombinant Human Collagen and Hyaluronic Acid for Immediate, Long-Lasting Results

    SEOUL, South Korea, Feb. 14, 2025 /PRNewswire/ — MAYPHARM CO., LTD. proudly introduces SKINCOLLA, the world’s first recombinant human collagen filler, marking a significant breakthrough in skin rejuvenation technology. Utilizing Demulcent™ Type I recombinant collagen, SKINCOLLA offers natural solution for achieving youthful, revitalized skin.

    MAYPHARM CO., LTD. Launches SKINCOLLA: The World’s First Recombinant Human Collagen Filler for Superior Skin Rejuvenation

    Revolutionizing Collagen Filler Technology

    SKINCOLLA is a game-changer in aesthetic treatments. It combines 100% human-identical recombinant collagen with Hyaluronic Acid (HA), providing immediate and lasting improvements to skin texture, elasticity, and hydration. This cutting-edge formula mimics the body’s natural collagen, restoring firmness, smoothness, and addressing common signs of aging such as wrinkles, sagging, and volume loss.

    Why Recombinant Human Collagen?

    Highly Body-Friendly: SKINCOLLA’s recombinant collagen is genetically identical to human collagen, ensuring superior biocompatibility and minimizing the risk of allergic reactions.

    With no synthetic additives, SKINCOLLA ensures optimal rejuvenation, making it a reliable choice for skin enhancement.

    Minimal Pain and No Downtime: Thanks to its structural similarity to natural collagen, SKINCOLLA injections are less painful, and the treatment involves no downtime, allowing patients to return to their daily activities immediately.

    Cultural Sensitivity: SKINCOLLA is designed with respect to diverse cultural and religious preferences, ensuring it’s suitable for patients from all backgrounds, including those adhering to Islamic guidelines.

    Cutting-Edge Technology for Long-Lasting Results

    The proprietary Demulcent™ Type I recombinant collagen in SKINCOLLA is produced in a controlled, high-tech environment. The inclusion of 50mg of HA in the formula further enhances hydration, providing a dual-action solution that amplifies the rejuvenating effects.

    Who Can Benefit from SKINCOLLA?

    SKINCOLLA is ideal for individuals seeking:

    Natural, subtle results without the “overdone” look often associated with traditional fillers.

    Non-invasive skin rejuvenation to improve elasticity, firmness, and hydration.

    Long-term anti-aging benefits, boosting collagen production for sustained skin improvement.

    Indications for SKINCOLLA

    Facial Wrinkles: Neck wrinkles, nasolabial folds, forehead lines, crow’s feet, and marionette lines.

    Eyes: Dark circle reduction, eye wrinkles, and puffiness.

    Body: Skin tightening and brightening in areas such as hands, knees, elbows, and armpits.

    For more information about SKINCOLLA and other products from MAYPHARM CO., LTD., please visit www.maypharm.net or contact sales@maypharm.co.kr.

    Photo – https://mma.prnewswire.com/media/2620398/MAYPHARM_CO_LTD_Launches_SKINCOLLA_The_World_s_First_Recombinant_Human.jpg

    Cision View original content:https://www.prnewswire.co.uk/news-releases/maypharm-co-ltd-launches-skincolla-the-worlds-first-recombinant-human-collagen-filler-for-superior-skin-rejuvenation-302376946.html


    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Skye Africa Intelligence and ECSA-HC Sign Memorandum of Understanding to Scale AI-Enabled Health Solutions

    August 5, 2026

    Boao Forum: CRRC Zhuzhou Institute Outlines Core Technologies and Application-Driven Innovation for Green Industry Growth

    August 4, 2026

    Sungrow Powers Sierra Leone’s Energy Transformation with First National-Scale Power Project

    July 31, 2026

    Investec Selects Infosys Finacle SaaS Platform on Microsoft Azure for Digital Banking Transformation

    July 30, 2026

    Binance bStocks Reaches $500 Million in AUM as a New Generation of Investors Turns to Tokenized Stocks

    July 29, 2026

    Powering Exceptional Guest Experiences with Intelligent Energy: The Peech Hotel’s Journey with Sungrow

    July 23, 2026
    Latest News

    Magnitude 4.9 earthquake hits southwestern China in Sichuan

    August 8, 2026

    Obesity linked to 8.2% of Belgium deaths in new health report

    August 8, 2026

    EU Commission signs contract to expand IRIS2 satellite constellation

    August 8, 2026

    China tightens drone exports in wider US countermeasures

    August 6, 2026

    Moderna begins Ebola vaccine trial amid DR Congo outbreak

    August 5, 2026

    Guatemala raises red alert as Fuego volcano erupts

    August 5, 2026

    OECD inflation eases to 4.2% as lower energy rates take hold

    August 5, 2026

    Oil prices fall as Brent and WTI reach three-week lows again

    August 5, 2026
    © 2026 Sudan Guardian | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.